These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 11214237)
1. Properties of recombinant HtrA: an otitis media vaccine candidate antigen from non-typeable Haemophilus influenzae. Cates GA; Yang YP; Klyushnichenko V; Oomen R; Loosmore SM Dev Biol (Basel); 2000; 103():201-4. PubMed ID: 11214237 [TBL] [Abstract][Full Text] [Related]
2. Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats. Akkoyunlu M; Forsgren A APMIS; 1996 Oct; 104(10):709-17. PubMed ID: 8980621 [TBL] [Abstract][Full Text] [Related]
3. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Forsgren A; Riesbeck K; Janson H Clin Infect Dis; 2008 Mar; 46(5):726-31. PubMed ID: 18230042 [TBL] [Abstract][Full Text] [Related]
4. The Haemophilus influenzae HtrA protein is a protective antigen. Loosmore SM; Yang YP; Oomen R; Shortreed JM; Coleman DC; Klein MH Infect Immun; 1998 Mar; 66(3):899-906. PubMed ID: 9488373 [TBL] [Abstract][Full Text] [Related]
5. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. Bertot GM; Becker PD; Guzmán CA; Grinstein S J Infect Dis; 2004 Apr; 189(7):1304-12. PubMed ID: 15031801 [TBL] [Abstract][Full Text] [Related]
6. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672 [TBL] [Abstract][Full Text] [Related]
7. New vaccines against otitis media: projected benefits and cost-effectiveness. O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754 [TBL] [Abstract][Full Text] [Related]
8. Differential uptake and processing of a Haemophilus influenzae P5-derived immunogen by chinchilla dendritic cells. Novotny LA; Partida-Sánchez S; Munson RS; Bakaletz LO Infect Immun; 2008 Mar; 76(3):967-77. PubMed ID: 18160476 [TBL] [Abstract][Full Text] [Related]
9. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Murphy TF Expert Rev Vaccines; 2005 Dec; 4(6):843-53. PubMed ID: 16372880 [TBL] [Abstract][Full Text] [Related]
10. Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Novotny LA; Jurcisek JA; Godfroid F; Poolman JT; Denoël PA; Bakaletz LO Vaccine; 2006 May; 24(22):4804-11. PubMed ID: 16616975 [TBL] [Abstract][Full Text] [Related]
11. Prevention of otitis media: now a reality? Schuerman L; Borys D; Hoet B; Forsgren A; Prymula R Vaccine; 2009 Sep; 27(42):5748-54. PubMed ID: 19666154 [TBL] [Abstract][Full Text] [Related]
12. Investigation of the potential of a 48 kDa protein as a vaccine candidate for infection against nontypable Haemophilus influenzae. Webb DC; Otczyk DC; Cripps AW Vaccine; 2007 May; 25(20):4012-9. PubMed ID: 17379362 [TBL] [Abstract][Full Text] [Related]
13. A Protein E-PilA Fusion Protein Shows Vaccine Potential against Nontypeable Haemophilus influenzae in Mice and Chinchillas. Ysebaert C; Denoël P; Weynants V; Bakaletz LO; Novotny LA; Godfroid F; Hermand P Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31109946 [TBL] [Abstract][Full Text] [Related]
14. Identification of human T-cell epitopes and highly immunogenic analog peptides on the non-typeable Haemophilus influenzae P6 outer membrane protein. Ishida Y; Abe Y; Yanai M; Kobayashi H; Harabuchi Y Clin Immunol; 2006 Oct; 121(1):90-9. PubMed ID: 16901757 [TBL] [Abstract][Full Text] [Related]
15. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Mason KW; Zhu D; Scheuer CA; McMichael JC; Zlotnick GW; Green BA Vaccine; 2004 Sep; 22(25-26):3449-56. PubMed ID: 15308371 [TBL] [Abstract][Full Text] [Related]
16. Peptide and recombinant antigens for protection against bacterial middle ear infection. Bakaletz LO Vaccine; 2001 Mar; 19(17-19):2323-8. PubMed ID: 11257356 [TBL] [Abstract][Full Text] [Related]
17. A method for the purification and refolding of a recombinant form of the nontypeable Haemophilus influenzae P5 outer membrane protein fused to polyhistidine. Webb DC; Cripps AW Protein Expr Purif; 1999 Feb; 15(1):1-7. PubMed ID: 10024463 [TBL] [Abstract][Full Text] [Related]
18. Distribution of bacterial proteins in biofilms formed by non-typeable Haemophilus influenzae. Webster P; Wu S; Gomez G; Apicella M; Plaut AG; St Geme JW J Histochem Cytochem; 2006 Jul; 54(7):829-42. PubMed ID: 16549506 [TBL] [Abstract][Full Text] [Related]
19. Haemophilus influenzae luxS mutants form a biofilm and have increased virulence. Daines DA; Bothwell M; Furrer J; Unrath W; Nelson K; Jarisch J; Melrose N; Greiner L; Apicella M; Smith AL Microb Pathog; 2005 Sep; 39(3):87-96. PubMed ID: 16099134 [TBL] [Abstract][Full Text] [Related]
20. Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable Haemophilus influenzae: an unambiguous, multifaceted approach. Bolduc GR; Bouchet V; Jiang RZ; Geisselsoder J; Truong-Bolduc QC; Rice PA; Pelton SI; Goldstein R Infect Immun; 2000 Aug; 68(8):4505-17. PubMed ID: 10899849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]